Bison Capital Partners V, LP has announced the sale of Apex Innovative Sciences, Inc.

SANTA MONICA, CA (June 16, 2022) – Bison Capital Partners V, LP (“Bison Capital”) has announced the sale of Apex Innovative Sciences, Inc. (“Apex” or the “Company”) to CenExel Clinical Research, Inc. (“CenExel”). Apex is the industry-leading independent operator of clinical trial sites focused on complex clinical trial studies for central nervous system (“CNS”) indications. Apex was formed in 2019 in conjunction with Bison Capital’s investment and the merger of CNS Network and Hassman Research Institute, complemented by the acquisition of Clinical Trial Centers Alliance, a leading coordinator of clinical trial site studies for sponsors and clinical research organizations.

Download Full Press Release

About Apex Innovative Sciences, Inc.

PSS is an industry leader in the development of technology to produce micron-accuracy surface finishes. Under the well-recognized Lapmaster, Peter Wolters, Kehren, ELB, Micron, Aba, and REFORM brands, PSS has a proven history of successfully developing cost-effective processing solutions for the lapping, polishing, fine grinding, brush deburring, creep feed grinding, bore honing, double disc grinding, buffing through an expanding network of sales and services offices located throughout the world. The Company’s 9,000+ active global customers utilize precision abrasive finishing technology for various end-user precision finishing applications. PSS is headquartered in Mt. Prospect, IL, USA.


Bison Capital is a Los Angeles and New York based private equity firm that makes growth capital investments in middle‐market companies, public or private, for expansion, acquisitions, and balance sheet recapitalizations. The firm’s primary investment focus is partnering with entrepreneurs and management teams seeking capital to grow their businesses.